POLYamine treatment in elderly patients with Coronary Artery Disease (POLYCAD): study protocol for a Danish randomised, double-blind, placebo-controlled trial of spermidine treatment versus placebo.

Christian Velling Thorup, Chris Nørgaard Agerbo Jeppesen, Thomas Hvid Jensen, Andreas Bugge Tinggaard, Christian Lodberg Hvas, Charlotte Lock Rud, Maria Kreiberg Skou, Janne Kaergaard Mortensen, Fulvio Reggiori, Jörn Dengjel, Jakob Wang, Jean Farup, Niels Jessen, Won Yong Kim, Henrik Wiggers

Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 69, 8200, Aarhus N, Denmark. [email protected] of Cardiology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 69, 8200, Aarhus N, Denmark. [email protected]. · pubmed

Paper

Abstract

Coronary artery disease (CAD) remains a major cause of morbidity and mortality. Caloric restriction promotes cardiovascular health but is difficult to sustain. Spermidine, a naturally occurring polyamine and caloric-restriction mimetic, has been linked to improved longevity in epidemiological studies and shown to enhance autophagy, mitochondrial function, and cardiovascular ageing in preclinical models. This trial will investigate whether high-dose spermidine improves cardiac remodelling, exercise capacity, muscle mass, and systemic inflammation in elderly patients with CAD.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that high-dose spermidine treatment will improve cardiac remodelling, exercise capacity, muscle mass, and systemic inflammation in elderly patients with CAD. The study investigates a potential intervention that targets mechanisms associated with aging and longevity, specifically through the lens of a caloric-restriction mimetic.

Author of this paper? Send a correction.